Ptc Therapeutics (PTCT) Profit After Tax (2012 - 2026)

Ptc Therapeutics' Profit After Tax history runs 15 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 100.32% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$186.7 million, a 131.39% decrease from a year earlier, with the FY2025 full-year figure at $682.6 million, up 287.9% from the prior year.
• Profit After Tax improved to -$2.8 million in Q1 2026 per PTCT's latest filing, from -$135.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $866.6 million in Q1 2025 and bottomed at -$198.9 million in Q2 2023.
• The 5-year median for Profit After Tax is -$109.3 million (2022), against an average of -$51.1 million.
• Biggest YoY gain for Profit After Tax was 1046.28% in 2025; the steepest drop was 104.85% in 2025.
• Year by year, Profit After Tax stood at -$170.9 million in 2022, then rose by 8.83% to -$155.8 million in 2023, then soared by 57.71% to -$65.9 million in 2024, then sank by 104.85% to -$135.0 million in 2025, then surged by 97.92% to -$2.8 million in 2026.
• Per Business Quant, the three latest PTCT Profit After Tax figures stand at -$2.8 million (Q1 2026), -$135.0 million (Q4 2025), and $15.9 million (Q3 2025).